The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector ...

Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GlaxoSmithKline signed a development and commercialization agreement with Human Genome Sciences (NASDAQ ...

GSK is also running a phase 3 combination study of Benlysta with rituximab, BLISS-BELIEVE, and the hope is that using the duo could drive the disease into clinical remission, according to Miels.

GSK plc today announced that the US Food and Drug Administration has approved Benlysta for the treatment of children aged 5 to 17 with active lupus nephritis who are receiving standard therapy.

GSK’s 2016 audited financials state that “Sales of Benlysta were £306 million(=$323 million), up 19%, with sales in the US of £277 million(= $290 million), up 18% with ongoing demand growth.” ...

LONDON, Dec. 18, 2019 /PRNewswire/ -- GSK today announced positive headline results for intravenous (IV) Benlysta (belimumab) in the largest controlled phase 3 study in active lupus nephritis (LN ...

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in.On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the ...